Abstract: The present invention provides tumor-targeting nanoplexes. Generally, a tumor-targeting nanoplex is a chemotherapeutic agent DNA conjugate with a first tumor-targeting agent and an optional second tumor-targeting agent linked thereto, such as a doxorubicin plasmid DNA conjugate and a linear histidine-lysine peptide with an optional cRGD-PEG-H3K4b second targeting agent. Also provided are methods for treating a cancer in a subject and for decreasing growth of a tumor in a cancer in a subject in need thereof in which the tumor targeting nanoplex is administered.

Abstract: Provided herein is a method for treating a cancer in a subject by quantitating the concentration of a soluble form of Semaphorin 4D (sSema4D) in a blood sample obtained from the subject and administering an immunotherapy when the blood concentration of sSema4D is below a threshold value of 155 ng/ml. Also provided is a method for determining the continued susceptibility of a tumor tissue to immunotherapy in a subject by identifying the inflammatory subtype of the tumor tissue from a blood sample from the subject and administering immunotherapy over at least one interval as long as the tumor tissue exhibits an inflamed subtype.

Abstract: Provided herein are protein translation inhibitors and pharmaceutical compositions thereof that bind to an RNA Recognition motif in heterogeneous ribonucleoprotein A18 to inhibit binding to mRNA transcripts thereby inhibiting protein synthesis. Also provided is a method for treating a cancer by administering a pharmaceutically acceptable amounts of at least one of the protein translation inhibitors.

Abstract: Provided herein are methods to predict pain sensitivity and pain intensity to prolonged pain in a subject. Electroencephalograms are recorded in a pain-free state or, alternatively, in a pain-free state and after applying a prolonged pain stimulus in a prolonged pain state. Pain-free and prolonged pain peak alpha frequencies or ?PAF are measured. These values correlate negatively with the likelihood of increased pain sensitivity and increased pain intensity. Also provided is a method for predicting a likelihood of chronic pain in a subject after a medical procedure and designing a plan to treat the chronic pain.

Abstract: Provided herein is a method for reducing resistance in an individual having a drug resistant cancer, for example, a BRAF inhibitor resistant cancer. A Hippo signaling pathway inhibitor such as a Yes-associated protein 1 (YAP1) inhibitor, a Transcriptional Coactivator with PDZ-binding motif (TAZ) inhibitor, a Transcription enhancer domain (TEAD) inhibitor or a combination of these is administered. Also provided is a method of treating BRAF inhibitor resistance in an individual with a BRAF inhibitor resistant cancer, for example, malignant melanoma, with a Hippo signaling pathway inhibitor, such as Verteporfin, and a BRAF inhibitor.

Abstract: Techniques for imaging radioactive emission in a target volume include collecting from each of multiple detectors in a Compton camera, within a coincidence time interval, location and deposited energy from an interaction associated with each high energy particle source event in a target volume, for N source events. A cone of possible locations for each source event is determined based on the locations and deposited energies collected. A SOE algorithm is initiated by selecting a random location on the cone and generating a histogram that indicates, a count of the selected locations that occur inside each voxel of the target volume. N solution locations for the N source events are determined after L iterations by updating the selected location on a corresponding cone based at least in part on values of the counts in the histogram excluding the current source event. A solution is presented on a display device.

Abstract: Provided herein are methods for treating a bone-related disorder in a subject. At least one of a microtubule altering drug, for example, a microtubule disrupting drug or a microtubule stabilizing drug, a TRPV4 agonist or a NOX2 activator is administered to the subject. Also provided are related methods for treating a bone-related disorder in the subject, by further administering at least one of an anti-sclerostin agent, a parathyroid hormone agonist, a bisphosphonate, an estrogen mimic, or a selective estrogen receptor modulator is further administered to the subject with the at least one of a microtubule altering drug, a TRPV4 agonist or a NOX2 activator.

Abstract: Techniques for imaging radioactive emission in a target volume include collecting from each of multiple detectors in a Compton camera, within a coincidence time interval, location and deposited energy from an interaction associated with each high energy particle source event in a target volume, for N source events. A cone of possible locations for each source event is determined based on the locations and deposited energies collected. A SOE algorithm is initiated by selecting a random location on the cone and generating a histogram that indicates, a count of the selected locations that occur inside each voxel of the target volume. N solution locations for the N source events are determined after L iterations by updating the selected location on a corresponding cone based at least in part on values of the counts in the histogram excluding the current source event. A solution is presented on a display device.

Abstract: The present invention relates to an adjuvant derived from human lymphocytes. The adjuvant can be used in combination with traditional vaccines or cancer immunotherapy, to enhance the response of the patient's immune system to the vaccine or other immunotherapeutic agent. The adjuvant is derived from the supernatant collected from cultured activated lymphocytes.

Abstract: The present provides methods and compositions that enable effective delivery of nucleic acids to desired cells, including to a solid organ such as a mammalian heart. The methods and compositions enable effective gene transfer and subsequent expression to a majority of cells throughout a solid organ such as the heart. Methods and compositions of the invention preferably provide enhanced vascular permeability that enables increased gene transfer to targeted cells, but without significant degradation or injury to endothelial cell layers. Global delivery of nucleic acid to an intact heart has been achieved with as little as 2 minutes of intracoronary exposure to the administered nucleic acid.